Vitamin D Knowledge, Awareness, and Attitudes of Adolescents and Adults: A Systematic Review

Fitzgerald, John S.; Swanson, Brenna J; Larson‐Meyer, D. Enette

doi:10.1016/j.jneb.2023.04.010

Cited by 1 publication

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One factor contributing to this might be that the median age of the patients was 55 years, indicating that they are not inherently considered “old”. Another factor could be the increased awareness of vitamin D deficiency, leading older patients to potentially counteract low 25(OH)D levels [ 43 ]. Especially during retirement, older individuals tend to spend more time outdoors throughout the week compared to younger, employed individuals, resulting in higher vitamin D levels [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Course of Vitamin D Levels in Newly Diagnosed Non-Metastatic Breast Cancer Patients over One Year with Quarterly Controls and Substitution

Zemlin,

Altmayer,

Lang

et al. 2024

Nutrients

View full text Add to dashboard Cite

(1) Background: Vitamin D levels in patients remain inadequately understood, with research yielding inconsistent findings. Breast cancer patients, particularly due to oncological therapies, face an increased risk of osteopenia, which can be exacerbated by a vitamin D deficiency. (2) Methods: The prospective observational “BEGYN-1” study assessed serum 25(OH)D levels at baseline and quarterly thereafter. Clinical, pathological, nutritional, vitamin supplementation, and lifestyle data were recorded. (3) Results: Before treatment, 68.5% of patients were vitamin D deficient (<30 ng/mL), with 4.6% experiencing severe deficiency (<10 ng/mL). The median baseline 25(OH)D levels were 24 ng/mL (range: 4.8 to 64.7 ng/mL). Throughout the study, the median vitamin D levels increased to 48 ng/mL (range: 22.0 to 76.7 ng/mL). Before diagnosis, 16.7% received vitamin D substitution, and 97.8% received vitamin D substitution throughout the year with a median weekly dose of 20,000 IU. It took at least three quarterly assessments for 95% of patients to reach the normal range. A multiple GEE analysis identified associations between 25(OH)D levels and supplementation, season, age, VLDL, magnesium levels, and endocrine therapy. (4) Conclusions: Physicians should monitor 25(OH)D levels before, during, and after oncological therapy to prevent vitamin D deficiency and to adjust substitution individually. While variables such as seasons, age, VLDL, magnesium, diet, and oncological interventions affect 25(OH)D levels, supplementation has the greatest impact.

show abstract

Section: Discussionmentioning

confidence: 99%